Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BMEA Biomea Fusion, Inc.

Trading 03-04 14:27:28 EST

1.39

+0.06

+4.63%

High1.41	Low1.32	Vol538.10K
Open1.37	D1 Closing1.33	Amplitude6.77%
Mkt Cap98.39M	Tradable Cap79.65M	Total Shares70.70M
T/O738.26K	T/O Rate0.94%	Tradable Shares57.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BMEA","market":"US","secType":"STK","nameCN":"Biomea Fusion, Inc.","latestPrice":1.3916,"timestamp":1772652412591,"preClose":1.33,"halted":0,"volume":538101,"delay":0,"changeRate":0.046315789473684116,"floatShares":57237400,"shares":70703639,"eps":-2.204976,"marketStatus":"Trading","change":0.0616,"latestTime":"03-04 14:27:28 EST","open":1.365,"high":1.41,"low":1.32,"amount":738257.6218185,"amplitude":0.067669,"askPrice":1.4,"askSize":2690,"bidPrice":1.39,"bidSize":2270,"shortable":3,"etf":0,"ttmEps":-2.204976,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772658000000},"marketStatusCode":2,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":1.33,"preHourTrading":{"tag":"盘前","latestPrice":1.36,"preClose":1.33,"latestTime":"09:28 EST","volume":1407,"amount":1982.2800900000002,"timestamp":1772634522014,"change":0.03,"changeRate":0.022556,"amplitude":0.067744},"postHourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.33,"latestTime":"19:45 EST","volume":1745,"amount":2304.6174,"timestamp":1772585149505,"change":0.01,"changeRate":0.007519,"amplitude":0.022556},"volumeRatio":0.655013,"impliedVol":1.2359,"impliedVolPercentile":0.7689},"requestUrl":"/m/hq/s/BMEA/wiki","defaultTab":"wiki","newsList":[{"id":"2617955444","title":"Biomea Fusion management to meet virtually with Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2617955444","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617955444?lang=en_us&edition=fundamental","pubTime":"2026-03-04 23:46","pubTimestamp":1772639214,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on March 16 hosted by Craig-Hallum. Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-management-to-meet-virtually-with-craig-hallum-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-management-to-meet-virtually-with-craig-hallum-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4539","BMEA"],"gpt_icon":0},{"id":"2614086754","title":"Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614086754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614086754?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:32","pubTimestamp":1772019170,"startTime":"0","endTime":"0","summary":"Biomea Fusion ( ($BMEA) ) has provided an update. On February 25, 2026, Biomea Fusion updated and published a new corporate presentation for invest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomea-fusion-updates-corporate-presentation-on-metabolic-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomea-fusion-updates-corporate-presentation-on-metabolic-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BMEA","BK4539","BK4585"],"gpt_icon":0},{"id":"2612219404","title":"Biomea Fusion to Present at Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612219404","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612219404?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:01","pubTimestamp":1771502477,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire  on February 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL6fFQJc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","NDAQ","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","BK4139","IE00BGHQF748.EUR","LU2095319765.USD","BMEA","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4585","BK4539","IE00BKPKM429.USD","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2612078214","title":"Biomea Fusion to Participate at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2612078214","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612078214?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502400,"startTime":"0","endTime":"0","summary":"SAN CARLOS, Calif., Feb.  19, 2026  (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/19/3240949/0/en/Biomea-Fusion-to-Participate-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BMEA","BK4539"],"gpt_icon":0},{"id":"2603422596","title":"Biomea Fusion Highlights Diabetes Pipeline at JPM Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603422596","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603422596?lang=en_us&edition=fundamental","pubTime":"2026-01-15 05:37","pubTimestamp":1768426647,"startTime":"0","endTime":"0","summary":"The latest update is out from Biomea Fusion ( ($BMEA) ). On January 14, 2026, Biomea Fusion presented updated data on its diabetes and obesity pipe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomea-fusion-highlights-diabetes-pipeline-at-jpm-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomea-fusion-highlights-diabetes-pipeline-at-jpm-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0170899867.USD","LU2264538146.SGD","LU2756315664.SGD","LU0971096721.USD","LU0149725797.USD","BK4533","BK4516","LU0320765489.SGD","LU2430703178.SGD","BK4534","BK4139","LU2430703251.USD","LU0106831901.USD","IE00BBT3K403.USD","LU0265550946.USD","IE00BFXG1179.USD","LU1720051017.SGD","LU2746668461.USD","SG9999002224.SGD","SG9999002232.USD","LU1629891620.HKD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU1720051108.HKD","LU1244550221.USD","IE00BN8TJ469.HKD","LU0683600562.USD","LU2756315318.SGD","IE00B775SV38.USD","BMEA","IE00BHPRN162.USD","LU1267930490.SGD","LU2430703095.HKD","LU2106854487.HKD","IE00BZ1G4Q59.USD","BK4581","LU1548497426.USD","LU2023250330.USD","LU1363072403.SGD","LU1551013425.SGD","BK4539","LU0106261372.USD","LU0417517546.SGD","LU1917777945.USD","LU1670627923.USD","LU0787776722.HKD","LU2746668974.SGD","LU1084165304.USD","LU0211327993.USD","LU0251132253.USD"],"gpt_icon":0},{"id":"2603511630","title":"Biomea Fusion initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2603511630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603511630?lang=en_us&edition=fundamental","pubTime":"2026-01-14 04:20","pubTimestamp":1768335623,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of Biomea Fusion (BMEA) with a Buy rating and $8 price target Published first on TheFly – the ultimate source f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4585","BMEA"],"gpt_icon":0},{"id":"2603527681","title":"Biomea Fusion Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2603527681","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603527681?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:49","pubTimestamp":1768308540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 07:49 ET (12:49 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2602517002","title":"Biomea Fusion Inc. Announces 2026 Strategy Focusing on Advancing Icovamenib and BMF-650 Clinical Programs, Initiating Phase II Trials in Type 2 Diabetes and Continuing Oral GLP-1 Candidate Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517002","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517002?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222815,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc. Announces 2026 Strategy Focusing on Advancing Icovamenib and BMF-650 Clinical Programs, Initiating Phase II Trials in Type 2 Diabetes and Continuing Oral GLP-1 Candidate Development. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL8JnFlg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BKPKM429.USD","SG9999014013.SGD","BK4588","IE00BGHQF748.EUR","SG9999014005.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","BK4139","BK4539","LU2210150020.SGD","BK4585","BMEA","IE00B64PRP62.GBP","SG9999014039.USD","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2591310624","title":"Director and Officer Rainer M. Erdtmann Acquires Common Shares of Biomea Fusion Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2591310624","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591310624?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:15","pubTimestamp":1765833343,"startTime":"0","endTime":"0","summary":"Rainer M. Erdtmann, Director and Officer of Biomea Fusion Inc., has reported the acquisition of common shares of Biomea Fusion Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL5JkpVp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director and Officer Rainer M. Erdtmann Acquires Common Shares of Biomea Fusion Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BMEA","BK4539"],"gpt_icon":0},{"id":"2590320924","title":"Biomea Fusion Highlights Icovamenib Data at WCIRDC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590320924","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590320924?lang=en_us&edition=fundamental","pubTime":"2025-12-10 07:35","pubTimestamp":1765323330,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc. participated in the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease , where Dr. Ralph DeFronzo, a leading expert in diabetes, delivered a presentation on the future of menin inhibitors and discussed the company's investigational therapy, icovamenib. The event featured a scientific session and an online interview highlighting the clinical results and potential of icovamenib as a disease-modifying therapy for diabetes, including its effects when combined with GLP-1 based therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire  on December 09, 2025, and is solely responsible for the informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL4Bc42n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BGHQF748.EUR","BK4539","LU2210149790.SGD","NDAQ","BK4588","SG9999014005.SGD","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD","BMEA","LU2210150020.SGD","BK4139","SG9999014013.SGD"],"gpt_icon":0},{"id":"2589781231","title":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589781231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589781231?lang=en_us&edition=fundamental","pubTime":"2025-12-06 03:14","pubTimestamp":1764962096,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companiesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL6N3XB0IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTAN","S","HL","AES","LU1150488218.USD","OMC","PKG","PSN","HPE","EUDA","FSLY","LU0128525929.USD","AUB","FCX","ITT","XOM","IOT","ZUMZ","ALB","PRAX","WBD","CDE","EXE","BMEA","DBRG","TRMB","VSCO","ROL","AMLX","DELL","LU0128525689.USD","LU0320765646.SGD","COO","ULTA","CHPT","INTS","HUM","EQT","TE","SCCO","LUV","RBRK","FANG","TARA"],"gpt_icon":1},{"id":"2589180868","title":"BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret","url":"https://stock-news.laohu8.com/highlight/detail?id=2589180868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589180868?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:22","pubTimestamp":1764944543,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's SecretEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning Ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL6N3XB0LA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4123","PKG","SGXZ23171101.USD","LU0300736062.USD","PSN","RGEN","HPE","TRMB","TARA","CHPT","LU0368265764.SGD","ULTA","LU2401740654.USD","ZUMZ","WBD","INTS","LU1863844665.USD","ROL","SWR.UK","89888","LU1989764664.SGD","LU0942090050.USD","RBRK","VSCO","LU0821914370.USD","LUV","LU1048596156.SGD","LU2477742899.HKD","LU1232071149.USD","BK4614","TTAN","SW","LU1280957306.USD","S","IE00B0JY6N72.USD","BK4170","LU0719512351.SGD","BMEA","LU1035775433.USD","LU2039709279.SGD","QCLS","IOT","COO"],"gpt_icon":1},{"id":"2589894293","title":"BUZZ-Biomea Fusion rises as diabetes drug shows promise","url":"https://stock-news.laohu8.com/highlight/detail?id=2589894293","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589894293?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:18","pubTimestamp":1764937132,"startTime":"0","endTime":"0","summary":"BUZZ-Biomea Fusion rises as diabetes drug shows promise** Shares of drug developer Biomea Fusion BMEA.O rise 3.4% to $1.23 premarket** Co says experimental drug, icovamenib, helped patients with severe type 2 diabetes maintain better blood sugar control nine months after treatment** Study presented at World Congress on Insulin Resistance in Los Angeles, co says** BMEA says drug aims to restore insulin-producing cells; tested in adults who failed up to three standard therapies** No serious side effects reported; further trials planned with GLP-1 users later this year, says co** As of last close, stock down ~69% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL4N3XB0X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","BK4539","BK4139","BK4585"],"gpt_icon":0},{"id":"2589894656","title":"Biomea Fusion Reports Durable Glycemic Improvements with Icovamenib in Type 2 Diabetes Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589894656","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589894656?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:00","pubTimestamp":1764936016,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc. announced the presentation of results from its COVALENT-111 clinical study at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease , held December 3-6, 2025, in Los Angeles. The study evaluated icovamenib, a selective menin inhibitor, in adults with severe insulin-deficient type 2 diabetes. According to the company, icovamenib demonstrated durable glycemic and C-peptide improvements up to 9 months after the last dose, with higher HbA1c reduction associated with greater drug exposure. The treatment was reported to be generally well-tolerated, with no adverse-event related discontinuations or serious adverse events. The full abstract will be published in Metabolism: Experimental and Clinical, and the presentation will be available on Biomea Fusion's Investor Relations page.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8TmX0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4539","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","LU2095319765.USD","NDAQ","BK4139","IE00B64PRP62.GBP","BK4112","BK4585","BMEA","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2589894588","title":"Biomea Fusion Presents Covalent-111 Study Results at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589894588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589894588?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:00","pubTimestamp":1764936001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA1C6G1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMEA","BK4139","BK4585","BK4539"],"gpt_icon":0},{"id":"2589837434","title":"Interim CEO Michael J.M. Hitchcock Reports Acquisition of Biomea Fusion Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589837434","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589837434?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:15","pubTimestamp":1764882948,"startTime":"0","endTime":"0","summary":"Michael J.M. Hitchcock, Interim CEO and Director of Biomea Fusion Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9KzrP5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Interim CEO Michael J.M. Hitchcock Reports Acquisition of Biomea Fusion Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","BK4139","BK4539","BK4585"],"gpt_icon":0},{"id":"2588306620","title":"Biomea Fusion Inc. CEO and Director Rainer M. Erdtmann Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588306620","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588306620?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:15","pubTimestamp":1764710136,"startTime":"0","endTime":"0","summary":"Rainer M. Erdtmann, Director and Officer at Biomea Fusion Inc., reported an acquisition of common shares of Biomea Fusion Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL3q1qbG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Biomea Fusion Inc. CEO and Director Rainer M. Erdtmann Reports Acquisition of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BMEA","BK4539","BK4139"],"gpt_icon":0},{"id":"2588703866","title":"Biomea Fusion Unveils Positive Long-Term Icovamenib Data in Type 2 Diabetes at WCIRDC","url":"https://stock-news.laohu8.com/highlight/detail?id=2588703866","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588703866?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:10","pubTimestamp":1764623411,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc. announced that it will present long-term follow-up data on icovamenib, a menin inhibitor targeting β-cell restoration in insulin-deficient type 2 diabetes, at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease  in Los Angeles, California. The oral presentation, scheduled for December 5, 2025, will feature results from the COVALENT-111 study, highlighting Week 52 data on glycemic and C-peptide improvements in patients. The presentation is one of six selected for oral delivery at the congress, with posters and presentations to be made available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL1nYCjr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4539","BK4588","BK4585","BK4139","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","BMEA"],"gpt_icon":0},{"id":"2588703853","title":"Biomea Fusion Announces Oral Presentation of Icovamenib at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588703853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588703853?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:10","pubTimestamp":1764623400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA63KJJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","BMEA","BK4585"],"gpt_icon":0},{"id":"2588087777","title":"Biomea Fusion Grants Stock Options to New Employee Under 2023 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588087777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588087777?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:05","pubTimestamp":1764623107,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc. has granted a new employee non-qualified stock options to purchase 7,500 shares of the company's common stock. The options will vest at a rate of 1/16 on a quarterly basis over four years, contingent on the employee's continued employment with the company. This award was made under Biomea Fusion's 2023 Inducement Equity Plan, adopted by the board of directors on November 17, 2023.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLcby0TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","BMEA","LU2095319765.USD","BK4539","LU2210149790.SGD","BK4112","NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","BK4585","BK4588","LU0314104364.USD","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biomeafusion.com","stockEarnings":[{"period":"1week","weight":0.0153},{"period":"1month","weight":0.1875},{"period":"3month","weight":0.2667},{"period":"6month","weight":-0.2732},{"period":"1year","weight":-0.4962},{"period":"ytd","weight":0.0726}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0052},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.1654},{"period":"ytd","weight":-0.0023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.06322},{"month":2,"riseRate":0.4,"avgChangeRate":0.025302},{"month":3,"riseRate":0.2,"avgChangeRate":0.134602},{"month":4,"riseRate":0,"avgChangeRate":-0.168176},{"month":5,"riseRate":0.6,"avgChangeRate":0.133765},{"month":6,"riseRate":0.4,"avgChangeRate":0.081609},{"month":7,"riseRate":0.4,"avgChangeRate":-0.019311},{"month":8,"riseRate":0.8,"avgChangeRate":0.078281},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012411},{"month":10,"riseRate":0.2,"avgChangeRate":-0.126858},{"month":11,"riseRate":0.4,"avgChangeRate":-0.034764},{"month":12,"riseRate":0.4,"avgChangeRate":-0.114655}],"exchange":"NASDAQ","name":"Biomea Fusion, Inc.","nameEN":"Biomea Fusion, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biomea Fusion, Inc.,BMEA,Biomea Fusion, Inc.股票,Biomea Fusion, Inc.股票老虎,Biomea Fusion, Inc.股票老虎国际,Biomea Fusion, Inc.行情,Biomea Fusion, Inc.股票行情,Biomea Fusion, Inc.股价,Biomea Fusion, Inc.股市,Biomea Fusion, Inc.股票价格,Biomea Fusion, Inc.股票交易,Biomea Fusion, Inc.股票购买,Biomea Fusion, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}